Castle biosciences inc.

Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Castle Biosciences, Inc. 2022 Inducement Plan (Full title of the plan) Derek J. Maetzold . President and Chief Executive Officer . Castle Biosciences, Inc. 505 S. Friendswood Drive, Suite 401 . Friendswood, Texas 77546 (866) 788-9907Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ...

Castle Biosciences, Inc. 9,614 followers. 1w. JUST RELEASED: Castle Biosciences announces financial results for the 2nd quarter and six months ended 6/30/2023. Highlights: Q2 2023 revenue ...

Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...

Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.Castle Biosciences, Inc. | 10,149 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests …Nov 14, 2023 · Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. 5 Castle Biosciences, Inc, 505 S. Friendswood Dr., Ste 400, Friendswood, TX, 77546, USA. [email protected]. PMID: 35216597 PMCID: PMC8876832 DOI: 10.1186/s13000-022-01211-w Abstract Background: To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the …

Also on June 6, 2023, the Reporting Person transferred 149,000 shares of Castle Biosciences, Inc. common stock to the DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the …

Mar 20, 2023 · A look at the shareholders of Castle Biosciences, Inc. (NASDAQ:CSTL) can tell us which group is most powerful. The group holding the most number of shares in the company, around 85% to be precise ...

Our DecisionDx-UM Seq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as ... 3 Castle Biosciences, Inc, Friendswood, Texas. 4 University of Rochester, Rochester, New York. 5 Icahn School of Medicine at Mount Sinai, New York, New York; Arkansas Dermatology Skin Cancer Center, Little Rock, Arkansas. 6 Oregon Health & Science University, Portland, Oregon.Castle Biosciences is a commercial stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more ...you invested in castle biosciences, inc. and it’s time to vote! this is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on may 25, 2023 at 10:00 a.m. edt at the omni william penn hotel, 530 william penn place, pittsburgh, pennsylvania 15219. ...Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.DecisionDx-Melanoma is a validated 31-gene expression profile (GEP) test that was developed to identify the risk of recurrence or metastasis including the likelihood of sentinel lymph node positivity for patients with stage I, II, or III melanoma and inform patient management decisions. The DecisionDx-Melanoma test accurately and independently ...

Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.Our DecisionDx-UM Seq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as ...May 15, 2023 · FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected ... Also on June 6, 2023, the Reporting Person transferred 149,000 shares of Castle Biosciences, Inc. common stock to the DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the …Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.FRIENDSWOOD, Texas, March 10, 2023--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm …Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. Skip to content. COVID-19 Response. Customer Service: 866-788-9007. CLINICIAN PORTAL. ORDER TEST. COVID-19 Response. ORDER TEST.

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ETCompany Participants. Camilla Zuckero - Executive Director of Investor Relations and Corporate ...Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%) After... Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer, and as a member of our board of ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.

He received a B.S. degree in molecular biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences’ technologies. Bob Cook has served as our Senior Vice President, Research & Development since September 2020, previously serving as our Vice ...

May 3, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.80 per share a year ago. Mar 20, 2023 · A look at the shareholders of Castle Biosciences, Inc. (NASDAQ:CSTL) can tell us which group is most powerful. The group holding the most number of shares in the company, around 85% to be precise ... Nov 14, 2023 · Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Problem Resolution Specialist at Castle Biosciences, Inc. 1y Report this post I love working at Castle!! Castle Biosciences, Inc. 10,111 followers 1y ...FRIENDSWOOD, Texas- Jan. 13, 2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.5 Castle Biosciences, Inc, 505 S. Friendswood Dr., Ste 400, Friendswood, TX, 77546, USA. [email protected]. PMID: 35216597 PMCID: PMC8876832 DOI: 10.1186/s13000-022-01211-w Abstract Background: To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the …Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Jul 10, 2023 · Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Oct 19, 2021 · October 19, 2021 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management ... About Castle Biosciences. Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. …Instagram:https://instagram. finance and investmentsutxxinteractive brokers mutual fundsbest companies to day trade At closing, Castle will pay $65.0 million in initial consideration to AltheaDx security holders, which will consist of $32.5 million in cash, subject to adjustments for cash, debt, transaction ... soilbuild singaporetslq etf Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. american tower reit FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating ...Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.